Dr. Flinn on FDA Approval of Frontline Brentuximab Vedotin With AVD in Hodgkin Lymphoma
March 20th 2018
Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of brentuximab vedotin (Adcetris) combined with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for patients with advanced classical Hodgkin lymphoma.